Despite approval of JAK inhibitors and novel agents for patients with myelofibrosis (MF), disease-modifying responses remain limited and hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment option. Numbers of HSCT continue to increase worldwide for MF, but its inherent therapy-related morbidity and mortality limit its use for many patients. Furthermore, MF patients often present at older age, with cytopenia, splenomegaly, and severe bone marrow …